iNKT Cells and Their Impact on Immune Health
iNKT cells bridge innate and adaptive immunity, influencing immune responses through diverse subsets, activation mechanisms, and interactions with other cells.
iNKT cells bridge innate and adaptive immunity, influencing immune responses through diverse subsets, activation mechanisms, and interactions with other cells.
Immune health relies on a diverse network of cells that detect and respond to threats. Among these, invariant natural killer T (iNKT) cells bridge innate and adaptive immunity. Unlike conventional T cells, they recognize lipid antigens presented by the CD1d molecule, enabling rapid immune responses.
Understanding iNKT cells is important because they influence inflammation, infection control, and autoimmune regulation. Their ability to modulate immune activity makes them a key focus in immunotherapy research.
iNKT cells are categorized into distinct subsets based on cytokine secretion profiles and functional characteristics. Identified through transcription factor expression and surface markers, these subsets contribute to diverse physiological processes. Each plays a specialized role in immune regulation.
This subset is defined by T-bet expression, a transcription factor linked to type 1 immune responses. iNKT1 cells predominantly produce interferon-gamma (IFN-γ), a cytokine central to cellular immunity. They also express high levels of NK1.1 in mice, distinguishing them from other subsets.
Functionally, iNKT1 cells exhibit cytotoxic activity, producing granzyme B and perforin to induce target cell lysis. Enriched in the liver, they contribute to immune surveillance and inflammatory responses. Research in Nature Immunology (2018) highlighted their role in early immune signaling, particularly in pathogen detection.
Defined by GATA3 expression, iNKT2 cells are associated with type 2 immune responses. They secrete interleukin-4 (IL-4) and interleukin-13 (IL-13), which regulate tissue repair and allergic reactions. Unlike iNKT1 cells, they exhibit lower cytotoxic potential but contribute to immune modulation.
Predominantly found in the thymus and lungs, iNKT2 cells influence local immune environments. Research in The Journal of Experimental Medicine (2020) demonstrated their role in regulating eosinophilic inflammation in asthma models by releasing IL-4, which can suppress excessive immune activation.
This subset is distinguished by RORγt expression, a transcription factor essential for interleukin-17 (IL-17) production. iNKT17 cells primarily contribute to inflammation, particularly in barrier tissues such as the skin and intestines.
Compared to other subsets, iNKT17 cells favor mucosal and epithelial sites, suggesting a role in microbial homeostasis. A study in Cell Reports (2019) found that iNKT17 cells respond to microbial metabolites, secreting IL-17 to recruit neutrophils and aid tissue protection. However, dysregulated activity has been linked to chronic inflammation.
A relatively less studied subset, iNKT10 cells produce interleukin-10 (IL-10), an anti-inflammatory cytokine. They express high levels of E4BP4, a transcription factor linked to immune regulation.
Primarily located in adipose tissue, iNKT10 cells contribute to metabolic regulation. Research in Nature Medicine (2015) showed their role in preventing obesity-induced inflammation by secreting IL-10, which dampens pro-inflammatory signaling and reduces metabolic disorder risk. Their presence in fat tissue suggests broader immune-metabolic interactions.
iNKT cell activation is governed by their recognition of lipid antigens presented by CD1d. Unlike conventional T cells, which respond to peptide antigens via MHC molecules, iNKT cells detect glycolipids derived from pathogens, self-lipids, and dietary sources. This distinct antigen presentation pathway allows for rapid immune responses.
Antigen-presenting cells (APCs) such as dendritic cells, macrophages, and B cells internalize and process lipid-containing molecules. These lipids are loaded onto CD1d within endosomal compartments before being presented on the cell surface. The iNKT cell receptor, which exhibits minimal diversity, recognizes the CD1d-lipid complex with high affinity, triggering intracellular signaling cascades.
Upon engagement with CD1d, the TCR transmits signals through ITAMs in the CD3 complex. This activates Src family kinases, recruiting downstream signaling molecules such as ZAP-70 and LAT. The subsequent activation of transcription factors like NF-κB, NFAT, and AP-1 orchestrates cytokine production and effector functions. The rapid release of cytokines following activation distinguishes iNKT cells from conventional T cells, which require prolonged stimulation.
Co-stimulatory signals refine iNKT cell activation, enhancing or modulating responses based on the microenvironment. Molecules such as CD28 and ICOS amplify cytokine secretion, while inhibitory receptors like PD-1 and Lag-3 regulate overactivation. Additionally, toll-like receptor (TLR) signaling in APCs influences CD1d expression and lipid antigen presentation, linking innate immune cues to iNKT cell activation.
iNKT cells are not uniformly distributed throughout the body but concentrate in specific tissues where they serve distinct roles. Their abundance varies significantly between organs, shaped by tissue-specific chemokines, adhesion molecules, and lipid antigen availability.
The liver harbors one of the highest proportions of iNKT cells, often exceeding 30% of total lymphocytes in mice. This enrichment aligns with its role as a filtration organ constantly exposed to bloodborne antigens. Hepatic iNKT cells express high levels of CXCR6, a chemokine receptor that promotes retention within sinusoidal spaces, positioning them near Kupffer and endothelial cells for lipid-derived signal monitoring.
In the lungs, iNKT cells localize within the mucosal environment, interacting with epithelial and antigen-presenting cells. Integrins such as α4β1 facilitate adherence to pulmonary tissues. The lung microenvironment influences iNKT cell composition, with iNKT2 and iNKT17 subsets responding to lipid antigens from inhaled particles and commensal microbes.
Adipose tissue represents another significant reservoir, where iNKT cells reside within visceral fat depots. Unlike their counterparts in lymphoid organs, adipose-resident iNKT cells skew toward regulatory functions, characterized by increased IL-10 production. Their localization is mediated by CCR7 and other chemokine receptors, enabling interactions with adipocytes and macrophages to regulate lipid metabolism and inflammation.
iNKT cells engage in extensive crosstalk with various lymphocyte populations, shaping immune dynamics through direct interactions and cytokine signaling. Their rapid cytokine secretion influences B cells, conventional T cells, and innate lymphoid cells, coordinating immune activity.
B cells are particularly affected by iNKT cells, especially through IL-4 and IL-21 production, which enhance antibody class switching. iNKT-derived IL-4 promotes germinal center formation within lymph nodes, facilitating B cell differentiation into plasma cells. This interaction is crucial in mucosal immunity, where lipid antigens presented by B cells can reciprocally activate iNKT cells, reinforcing antibody production.
iNKT cells also interact closely with CD4⁺ and CD8⁺ T cells, amplifying their responses. IFN-γ secretion creates an environment that enhances cytotoxic T lymphocyte (CTL) activity, promoting CD8⁺ T cell expansion and survival. Additionally, IL-2 production under certain conditions supports naïve T cell proliferation, positioning iNKT cells as facilitators of adaptive immune priming.
iNKT cells contribute to host defense by responding rapidly to pathogens through cytokine secretion and cytotoxic activity. Their ability to recognize microbial lipid antigens enables early immune responses against bacterial, viral, fungal, and parasitic infections.
In bacterial infections, iNKT cells aid pathogen clearance by recognizing lipid-based antigens from bacterial cell walls. For example, Mycobacterium tuberculosis, the causative agent of tuberculosis, produces glycolipids recognized by iNKT cells, leading to IFN-γ production and macrophage activation. Similarly, in Borrelia burgdorferi infections, which cause Lyme disease, iNKT cells facilitate bacterial clearance by modulating dendritic cell activity.
In viral infections, their role varies by pathogen. While iNKT cells can enhance antiviral immunity through IFN-γ secretion, excessive activation has been linked to immunopathology in diseases such as influenza and hepatitis B. Their involvement in fungal and parasitic infections is less understood, but studies suggest they help control Candida albicans and Plasmodium species by promoting Th1 and Th17 responses.
iNKT cells influence autoimmune disease regulation, modulating immune responses at the intersection of protective immunity and pathological inflammation. Depending on the balance between pro-inflammatory and regulatory subsets, they can either suppress or exacerbate disease.
In multiple sclerosis (MS), reduced iNKT cell frequency has been observed in patients. iNKT-derived IL-4 and IL-10 may help suppress autoreactive T cells, making them potential therapeutic targets. Conversely, in systemic lupus erythematosus (SLE), iNKT cells often exhibit altered cytokine profiles that exacerbate immune dysregulation.
Rheumatoid arthritis (RA) presents a dual role for iNKT cells, with iNKT1 contributing to joint inflammation while iNKT10 counteracts tissue damage. These findings highlight the complexity of iNKT cell interactions in autoimmune settings, suggesting that therapeutic strategies must be tailored to specific immune environments.